Menu

CNS Connect

A neurodegenerative resource newsletter for providers, to help you stay informed on the rapidly evolving neurodegenerative research landscape.

FDA-cleared tests

Currently approved blood-based biomarkers

Last updated September 2026

Test Analyte(s) FDA status Intended use Care setting Ordering codes
Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio Fujirebio pTau217 and Aβ42, reported as a ratio FDA cleared May 2025 Aids in assessing amyloid plaque pathology in adults 55 and older with cognitive decline. Used alongside other clinical information, not as a stand-alone test. Specialty care Labcorp 50809
Quest 14258
Elecsys® Phospho-Tau (181P) — pTau181 Roche / Eli Lilly pTau181 FDA cleared October 2025 Cleared for initial frontline use to rule out Alzheimer's-related amyloid pathology in adults 55 and older. Primary care Labcorp 483745
Quest 13690
PrecivityAD2 C2N Diagnostics p-tau217 and Aβ42/40 ratio, by mass spectrometry FDA cleared August 2026 For adults 40 and older with cognitive symptoms. Returns an amyloid probability score to help determine whether amyloid plaques are present. Specialty care C2N Diagnostics 1001
Elecsys® Phospho-Tau (217P) Plasma Roche / Eli Lilly pTau217 FDA cleared August 2026 Aids in identifying amyloid pathology in adults 55 and older, supporting both rule-in and rule-out assessment in routine laboratory workflows. Primary & specialty care Labcorp 484390
Quest 13825
Resource library

Tools & links to help support your patients.

A growing collection of guides, recorded sessions, and trial information for providers caring for patients with cognitive concerns.

Showing 7 of 7 resources

This library is updated as the team publishes new material. Have a resource to suggest? Email us below.

What you’ll receive

Inside every issue.

By signing up for this quarterly newsletter, you’ll receive information on:

  • FDA approvals, authorizations, and clearance updates.
  • Current and emerging blood-based biomarkers (BBMs).
  • News on Alzheimer's disease therapies and treatment pathways.
  • Guidance on incorporating cognitive assessments and BBMs into office workflows.
  • Resources to assist with early detection of cognitive decline.
  • Invitations to CME-accredited webinars, meetings, and educational events.
  • Clinical trial opportunities.
Contact

Reach out to the CNS Connect team.

Questions, resource suggestions, or an event you’d like us to cover.

CNS Connect Team

Get in touch.

Our team will follow up directly.

Email [email protected]

    By submitting you agree to be contacted by GAP about your inquiry.